(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 7. Treatment with dopamine agonists increases the D2 receptor density at plasma membrane and decreases the D2 level from sGi2-D2 complex. (A) Incubation of BHK cells expressing D2S and sGi2 protein with 10 µM dopamine (D) or 5 µM quinpirole (Q) for 30 minutes showed a significant increase (18%) in D2 receptor localization at plasma membrane. By contrast, however, treatment with antagonist [raclopride (R), 5 µM] produced no effect. Controls are from C1 to C5 (C1, cells expressing D2S receptors alone and treated with dopamine; C2, cells treated with quinpirole; C3, cells expressing G
i2 as well as D2S receptor and treated with dopamine; C4, cells treated with quinpirole; C5, cells expressing sGi2 and D2S receptor but left untreated). (B) Extracts of same cells as used in A were passed through sGi2 immunoaffinity columns and eluted to determine sGi2-bound D2S receptor in above conditions. Immunoblot assays show that agonist treatment resulted in loss of
75% (equals to 22% of the binding results) D2S component (49 kDa) from sGi2-D2S complex, whereas the level of sGi2 was the same in all conditions. (C) Average OD change in immunoblot experiments from B. Results show that only 28.6±2.48% and 25±2.78% of the D2S receptor remained bound in the sGi2-protein complex eluted from dopamine (D)-treated and quinpirole (Q)-treated cells, respectively. Values are representative of five different experiments.